RT Book, Section
A1 Ang, Elizabeth
A1 Sundel, Robert
A2 Zaoutis, Lisa B.
A2 Chiang, Vincent W.
SR Print(0)
ID 1146122322
T1 Kawasaki Disease
T2 Comprehensive Pediatric Hospital Medicine, 2e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071829281
LK accesspediatrics.mhmedical.com/content.aspx?aid=1146122322
RD 2024/04/25
AB Kawasaki  disease  (KD),  a  vasculitis  affecting  small-  and  medium-  sized  blood  vessels,  is  the  second  most  common  childhood  vasculitis,  and  the  most  common  cause  of  pediatric  acquired  heart  disease  in  the  developed  world.1  It  was  first  described  in  1967  and  initially  called  mucocutaneous  lymph  node  disease  because  of  the  predominant  clinical  features.  Affected  children  present  acutely  with  fever,  bilateral  nonexudative  conjunctivitis,  erythema  of  the  lips  and  oral  mucosa,  cervical  lymphadenopathy,  rash,  and  extremity  changes.  These  findings  are  usually  self-limited,  but  15%  to  25%  of  untreated  children  develop  coronary  artery  abnormalities,  putting  them  at  risk  for  developing  ischemic  heart  disease  or  sudden  death  later  in  life.2  Therapy  with  intravenous  immunoglobulin  in  the  acute  phase  is  aimed  at  reducing  inflammation,  thereby  minimizing  the  risk  of  coronary  artery  aneurysms  and  other  late  sequelae.